JSA
NVO

Jim Saulnier & Associates’s Novo Nordisk NVO Stock Holding History

Jim Saulnier & Associates’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$314K Hold
6,544
– – 0.13% 121
2026
Q1 		$241K Hold
6,544
– – 0.12% 126
2025
Q4 		$333K Hold
6,544
– – 0.17% 102
2025
Q3 		$363K Hold
6,544
– – 0.2% 91
2025
Q2 		$452K Buy
6,544
+230
+4% +$15.6K 0.31% 66
2025
Q1 		$438K Hold
6,314
– – 0.34% 60
2024
Q4 		$543K Hold
6,314
– – 0.47% 43
2024
Q3 		$752K Buy
+6,314
New +$842K 0.74% 31

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jim Saulnier & Associates's NVO Position: Q2 2026 in Review

Jim Saulnier & Associates held its Novo Nordisk (NVO) position steady in Q2 2026 at 6,544 shares worth $314K. The position accounts for 0.13% of the portfolio, ranked #121.

Jim Saulnier & Associates first reported a position in NVO in Q3 2024 and has held it in 8 quarters since. The position peaked at $752K in Q3 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Jim Saulnier & Associates held 6,544 shares of Novo Nordisk worth $314K as of Q2 2026.
  • Jim Saulnier & Associates left its Novo Nordisk share count unchanged in Q2 2026.
  • Novo Nordisk made up 0.13% of Jim Saulnier & Associates's portfolio in Q2 2026, its #121 holding.
  • Jim Saulnier & Associates first reported a position in Novo Nordisk in Q3 2024 and has held it in 8 quarters since.
  • Jim Saulnier & Associates's Novo Nordisk position peaked at $752K in Q3 2024.
  • 1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Jim Saulnier & Associates's 13F filing for Q2 2026, filed 28 Jul 2026.